Overview
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Eligibility
Inclusion Criteria:
- Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representatives(s)
- Ability to travel to the study site and adhere to study related follow-up examinations and/or procedures and provide access to participant's medical records
- Genetically confirmed neurological disorder
Exclusion Criteria:
- Participant has any condition that in the opinion of the Site Investigator would ultimately prevent the completion of study procedures
- Use of an investigational medication within less than 5 half-lives of the drug at enrollment